Yaron Werber

Yaron Werber of Citi maintained his "buy" rating on Amgen Inc (NASDAQ: AMGN). The target price for AMGN is set to $64.00. According to Citi, the market has overlooked competition to Amgen’s Epogen and Aranesp from Hematide. Citi expects this drug to pose threat to AMGN's base business from late...